SITE008-0052

completed

Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE008 (KOR) (Dr. Kim) · consented 2022-04-23

Adverse events

Serious AEs

Open data queries

Luna dropout signal

–

Adverse events

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-05-14 (study day 2); relationship: not assessed

severe assessed 2026-08-18

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-05-19 (study day 7); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Nausea — outcome: UNKNOWN; onset 2022-06-16 (study day 35); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-06-22 (study day 41); relationship: N

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-08-17 (study day 97); relationship: N

moderate assessed 2026-08-18

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-09-03 (study day 114); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-09-14 (study day 125); relationship: N

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.